文献速递肾小球疾病慢性肾脏病

狼疮肾炎患者羟氯喹血药浓度与疾病结局的关系

Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该回顾性观察研究纳入171例经活检证实的III、IV或V型狼疮肾炎患者,接受羟氯喹200-400 mg/日至少3个月并监测血药浓度。随访期间发生肾脏复发者平均羟氯喹浓度显著低于维持缓解者(0.59 vs 0.81 mg/L,P=0.005),提示目标浓度>0.6 mg/L可能降低复发风险。

要点

  • 狼疮肾炎患者羟氯喹血药浓度与肾脏复发风险相关。
  • 发生肾脏复发者平均羟氯喹浓度显著低于维持缓解者。
  • 建议羟氯喹最低目标浓度至少0.6 mg/L以减少复发。

核心结论

  • 羟氯喹血药浓度监测可能有助于识别不依从患者并给予支持。
  • 提议羟氯喹最低目标浓度至少0.6 mg/L以降低肾脏复发率,但需前瞻性研究验证。

研究设计与样本

  • 回顾性观察研究,数据来自临床和实验室记录。
  • 纳入171例经活检证实的ISN/RPS III、IV或V型狼疮肾炎患者,接受羟氯喹200-400 mg/日至少3个月并监测血药浓度。
  • 排除基线时接受肾脏替代治疗或失访的患者。

主要发现

  • 在171例患者中,共测量1282份样本的羟氯喹浓度。
  • 平均羟氯喹血药浓度为0.75±0.54 mg/L,呈双峰分布。
  • 羟氯喹浓度<0.20 mg/L(232份样本,18.1%)似乎定义了一个异常低浓度的独立组。
  • 基线时完全或部分缓解的患者中,随访期间发生肾脏复发者平均羟氯喹浓度显著低于维持缓解者(0.59 vs 0.81 mg/L;P=0.005)。
  • 数据提示狼疮肾炎患者羟氯喹目标浓度>0.6 mg/L(600 ng/mL)可降低肾脏复发可能性。

关键数值与推荐

  • 羟氯喹异常低浓度阈值:<0.20 mg/L(232份样本,18.1%)。
  • 建议羟氯喹最低目标浓度至少0.6 mg/L(600 ng/mL)以降低肾脏复发率。

临床怎么用

  • 对狼疮肾炎患者可考虑监测羟氯喹血药浓度以评估依从性。
  • 维持羟氯喹血药浓度至少0.6 mg/L可能有助于减少肾脏复发。

局限性

  • 回顾性观察研究设计。
  • 目标浓度需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydroxychloroquine (HCQ) is a recommended drug in systemic lupus erythematosus (SLE). It has a long terminal half-life, making it an attractive target for therapeutic drug monitoring. The aim of this study was to establish a relationship between blood HCQ concentration and lupus nephritis activity. METHODS: We conducted a retrospective observational study with data collected from clinical and laboratory records. Inclusion criteria were patients followed in the lupus clinic with biopsy-proven International Society of Nephrology/Renal Pathology Society Classes III, IV or V lupus nephritis on HCQ for at least 3 months (200-400 mg daily) and with HCQ levels measured during treatment. Exclusion criteria were patients on renal replacement therapy at baseline or patients lost to follow-up. RESULTS: In 171 patients, the HCQ level was measured in 1282 samples. The mean HCQ blood level was 0.75±0.54mg/L and it was bimodally distributed. An HCQ level <0.20 mg/L [232 samples (18.1%)] appeared to define a distinct group of abnormally low HCQ levels. For patients in complete or partial remission at baseline compared with those remaining in remission, patients with renal flare during follow-up had a significantly lower average HCQ level (0.59 versus 0.81 mg/L; P= 0.005). Our data suggest an HCQ target level to reduce the likelihood of renal flares >0.6 mg/L (600 ng/mL) in those patients with lupus nephritis. CONCLUSION: HCQ level monitoring may offer a new approach to identify non-adherent patients and support them appropriately. We propose an HCQ minimum target level of at least 0.6 mg/L to reduce the renal flare rate, but this will require a prospective study for validation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Cunha C, Alexander S, Ashby D, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant. 2018. PMID: 29186572. doi:10.1093/ndt/gfx318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。